Holdings – Page 2

Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases

7 months ago talkbio0Tagged DCLRE1B gene, Health Ventures, Holdings, multicatalytic endopeptidase complex, Nerve Degeneration, Neurodegenerative Disorders, Proteasome Activator Therapies, Protein Degradation, Metabolic

Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration

Catalent Reports Strong Q4 Results Amid Pending Acquisition by Novo Holdings

8 months ago talkbio0Tagged Acquisition (action), biotech, Catalent, Consumer health, Dosage Forms, Holdings, Q4, results

Catalent, Q4 Results, Novo Holdings, Acquisition, Pharmaceutical, Biotech, Consumer Health

Catalent’s Revival: Are the Dark Days Behind It Ahead of Novo Holdings Acquisition?

8 months ago talkbio0Tagged Acquisition (action), Catalent, day, Drug Industry, Holdings, Revival

Catalent, Novo Holdings, acquisition, pharmaceutical industry, revenue boost, dark days, revival

Rafael Holdings and Cyclo Therapeutics Merge to Accelerate Development of Niemann-Pick Disease Type C1 Treatment

9 months ago talkbio0Tagged Clinical Trials, Cyclo Therapeutics, Drug Development, Holdings, Niemann-Pick Disease, Type C1, Rafael, Trappsol Cyclo

Rafael Holdings, Cyclo Therapeutics, merger, Niemann-Pick Disease Type C1, Trappsol Cyclo, clinical trial, pharmaceutical development

Myricx Bio Secures £90m ($114m) Series A Financing to Advance Novel NMTi ADC Therapeutics

10 months ago talkbio0Tagged Bio, Eli Lilly, financing characteristics, Holdings, Malignant Neoplasms, Myricx, NMTi, Series, therapeutic autologous dendritic cells

Myricx Bio, Series A Financing, NMTi ADC Therapeutics, Novo Holdings, Lilly, Cancer Treatment

Novo, Gates, and Wellcome Join Forces with $300 Million Initiative to Tackle Global Infectious Diseases

1 year ago talkbio0Tagged Collaboration, Communicable Diseases, development aspects, Global Health, Holdings, Melinda, Microbicides, pandemic preparedness, research, Resistance (Psychotherapeutic), Trust (Social Behavior), Wellcome

Novo Holdings, Bill & Melinda Gates Foundation, Wellcome Trust, infectious diseases, global health, pandemic preparedness, antimicrobial resistance, research and development, funding, collaboration.

Novo Holdings Supports Reunion Neuroscience’s $103M Series A Funding for Pioneering Psychedelic Clinical Trials

1 year ago talkbio0Tagged Biotechnology, Funding, Health care facility, Holdings, Investments, mental health, mental health innovation, Neuroscience discipline, psychedelic clinical trials, Reunion Island, Series, venture

Novo Holdings, Reunion Neuroscience, Series A funding, psychedelic clinical trials, mental health treatments, mental health innovation, venture capital, biotechnology, healthcare investments.

Clasp Therapeutics Launches with $150M Series A Funding to Develop Next-Generation T Cell Engaging Immunotherapies

1 year ago talkbio0Tagged Ataxia Telangiectasia Mutated Proteins, Catalio Capital Management, cellular targeting, CEO, CLASRP gene, engagers, financing characteristics, HLA Molecule Profiling, Holdings, Personalized Off-the-Shelf Therapies, Robert Ross, T-Lymphocyte, Third Rock

Clasp Therapeutics, $150M Series A Financing, T Cell Engagers, Personalized Off-the-Shelf Therapies, Targeting Mutated Protein Fragments, HLA Molecule Profiling, Novo Holdings/ Third Rock Ventures/ Catalio Capital Management, CEO Robert Ross

Updated: Novo Holdings pays $16.5B to take Catalent private and sells three manufacturing sites to Novo Nordisk

1 year ago talkbio0Tagged Acquisition (action), deal, Holdings, Investments, Nordisk

Holdings, Nordisk, deal, Acquisition (action), Investments